EL7.AI
StocksMedium•9 November 2026•
3 min read

Apotea revenue rises 12.5% to SEK 1,990.4 million in third quarter

Key Facts

1Net revenue rose 12.5% to SEK 1,990.4 million in the third quarter of 2026.
2Adjusted operating profit was SEK 108.3 million, and its margin rose to 5.4%.
3Prescription product sales increased 18.9% to SEK 793.1 million.
4Net profit was SEK 81.8 million, compared with SEK 68.6 million in the third quarter of 2025.
5Operating cash flow fell to SEK 25.8 million from SEK 109.4 million a year earlier.

Apotea reported third-quarter results on November 5, 2026, with net revenue of SEK 1,990.4 million, up 12.5% from the same period last year. The company said in its report that revenue was SEK 1,769.3 million in the third quarter of 2025. Adjusted operating profit was SEK 108.3 million, compared with SEK 88.2 million a year earlier. The adjusted operating margin rose to 5.4% from 5.0%. Earnings per share also increased to SEK 0.79 from SEK 0.67 in the year-earlier quarter.

Revenue growth came alongside improvements in operating profitability, while management said prescription products were the main driver during the quarter. Sales of these products rose 18.9% to SEK 793.1 million from SEK 667.0 million a year earlier. The chief executive attributed the performance to prescription products, saying that "strengthening our offering to customers had a positive impact." Company figures show that sales in this business grew faster than total revenue, which rose 12.5%. Higher sales, together with an increase in the adjusted operating margin to 5.4%, supported operating profitability during the period.

Apotea posted net profit of SEK 81.8 million in the third quarter, compared with SEK 68.6 million in the same period of 2025. But cash flow from operating activities fell to SEK 25.8 million from SEK 109.4 million a year earlier. The decline in cash flow presents a different picture from the improvement in revenue and operating profit, as cash generated from operating activities fell despite the increase in net profit. Earnings per share rose to SEK 0.79 from SEK 0.67, alongside the increase in net profit. The results therefore reflect growth in revenue and profitability, alongside lower operating cash flow than in the year-earlier period.

For the first nine months of 2026, revenue rose 11.3% to SEK 5,953.6 million from SEK 5,349.1 million in the year-earlier period. Adjusted operating profit increased to SEK 314.3 million from SEK 279.9 million. These figures provide broader context for the third-quarter results: revenue growth was 11.3% over the nine months and 12.5% in the quarter alone. Adjusted operating profit for the period through September also increased from a year earlier. This cumulative performance came alongside growth in prescription product sales and an improved margin in the third quarter.

As it expanded its service, the company said that since September it has offered same-day delivery to 3.7 million people, every day of the week. The service announcement appeared in the third-quarter report, which said that strengthening the company's offering to customers had a positive impact. The chief executive had previously linked quarterly growth to prescription products, while the report did not detail how much delivery contributed to revenue. The company set February 4, 2027, as the date for reporting its 2026 annual results. That is the next financial report date listed on the company's investor calendar.